SWX:CMHCPharmaceuticals
Can Cosmo (SWX:CMHC) Re Rate As Hair Loss Data Raises Its Valuation Question?
Cosmo (SWX:CMHC) is back in focus after reporting 12 month Phase 3 data for its clascoterone 5% topical solution in male pattern hair loss, highlighting sustained efficacy and a safety profile comparable to vehicle.
See our latest analysis for Cosmo.
Despite the latest clascoterone update putting Cosmo back on investors’ radar, the stock has seen its share price fall 9.35% over the past month and 25.48% over the past quarter. At the same time, the 1 year total shareholder return of 7.43% and...